Combination treatment with corticosteroid, cyclosporine A, and mycophenolate in refractory nephrotic syndrome

2011 ◽  
Vol 75 (06) ◽  
pp. 511-517 ◽  
Author(s):  
H.R. Jang ◽  
H.W. Jung ◽  
Y.-J. Lee ◽  
J.E. Lee ◽  
W. Huh ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Cyclosporine A ◽  
Combination Treatment ◽  
Refractory Nephrotic Syndrome

scholarly journals Cyclosporine A for the treatment of refractory nephrotic syndrome with renal dysfunction

2013 ◽  
Vol 7 (2) ◽  
pp. 447-450 ◽  
Author(s):  
XIANG GAO ◽  
YIYI MA ◽  
LIJUN SUN ◽  
DONGPING CHEN ◽  
CHANGLIN MEI ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Renal Dysfunction ◽  
Cyclosporine A ◽  
Refractory Nephrotic Syndrome

Rituximab in refractory nephrotic syndrome

2009 ◽  
Vol 25 (3) ◽  
pp. 461-468 ◽  
Author(s):  
Agnieszka Prytuła ◽  
Kazumoto Iijima ◽  
Koichi Kamei ◽  
Denis Geary ◽  
Errol Gottlich ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Refractory Nephrotic Syndrome

scholarly journals All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome

2021 ◽  
Author(s):  
Mana Kobayashi ◽  
Yutaro Kageyama ◽  
Takashi Ando ◽  
Junko Sakamoto ◽  
Shohji Kimura
Keyword(s):  
Nephrotic Syndrome ◽  
Standard Deviation ◽  
Real World ◽  
Pediatric Patients ◽  
Safety And Efficacy ◽  
The Real ◽  
Post Marketing Surveillance ◽  
Post Marketing ◽  
Refractory Nephrotic Syndrome ◽  
Observation Period

Abstract Background Rituximab is conditionally approved in Japan for use in patients with refractory nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing surveillance study was conducted to confirm the real-world safety and efficacy of rituximab in patients of all ages with refractory nephrotic syndrome. Methods All patients scheduled to receive rituximab treatment for refractory nephrotic syndrome were eligible to register (registration: August 29, 2014 through April 15, 2016); the planned observation period was 2 years from the initiation of rituximab treatment (intravenous infusion, 375 mg/m2 once weekly for four doses). The study was conducted at 227 hospitals throughout Japan. Adverse drug reactions (ADRs) were collected for safety outcomes. The efficacy outcomes were relapse-free period and the degree of growth in pediatric (< 15 years) patients. Results In total, 997 (447 pediatric) patients were registered; 981 (445) were included in the safety analysis set; 852 (402) completed the 2-year observation period; and 810 (429) were included in the efficacy analysis set. Refractory nephrotic syndrome had developed in childhood for 85.0% of patients, and 54.6% were aged ≥15 years. ADRs were observed in 527 (53.7%) patients, treatment-related infection/infestation in 235 (24.0%) patients, and infusion reactions in 313 (31.9%) patients. The relapse-free period was 580 days (95% confidence interval, 511–664). There was a significant change in height standard deviation score (pediatric patients; mean change, 0.093; standard deviation, 0.637; P = 0.009). Conclusion The safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome were confirmed in the real-world setting. Clinical trial registration UMIN000014997.

scholarly journals The effectiveness of cyclosporine A for patients with steroid-resistant nephrotic syndrome

Medicine ◽  
2021 ◽  
Vol 100 (49) ◽  
pp. e28186
Author(s):  
Juan Lv ◽  
Shizhi Luo ◽  
Yunxia Zhang ◽  
Enlai Dai
Keyword(s):  
Nephrotic Syndrome ◽  
Cyclosporine A ◽  
Steroid Resistant ◽  
Steroid Resistant Nephrotic Syndrome

scholarly journals Possible mechanisms of LDL apheresis for pediatric patients with steroid resistant and refractory nephrotic syndrome

2010 ◽  
Vol 23 (2) ◽  
pp. 154-159
Author(s):  
Hiroaki Ueda ◽  
Yuko Akioka ◽  
Masakazu Miyamura ◽  
Kiyonobu Ishizuka ◽  
Mamiko Suehiro ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Pediatric Patients ◽  
Ldl Apheresis ◽  
Steroid Resistant ◽  
Refractory Nephrotic Syndrome

Cyclosporine A in the Treatment of a Patient with Immune Thrombocytopenia Accompanied by Myelodysplastic Syndrome and Nephrotic Syndrome

2003 ◽  
Vol 110 (1) ◽  
pp. 36-40 ◽  
Author(s):  
Soo-Jeong Park ◽  
Chi-Wha Han ◽  
Je-Hoon Lee ◽  
Hyeon-Seok Eom ◽  
Seung-Hun Lee ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Myelodysplastic Syndrome ◽  
Cyclosporine A ◽  
Immune Thrombocytopenia
Sign in / Sign up

Export Citation Format

Share Document